Kancera

Our vision is to develop pharmaceuticals that contribute to normalized lives for patients

New class of drugs for treatment of severe inflammatory conditions and resistant cancer

The fractalkine axis controls pro-inflammatory cells and cancer cells with precision

Our business

Kancera develops pharmaceuticals for life threatening diseases with high medical needs

Our science

Kancera develops a new class of drugs targeting the fractalkine axis

Our pipeline

Kancera’s two fractalkine blocking drug candidates are currently being studied in three ongoing clinical trials

CEO statement

“With the important milestones achieved in our ongoing clinical studies we have taken a major step forward with our fractalkine program.”

Peter Selin, CEO Kancera

Press Releases

2024-11-15
Interim Report Third Quarter 2024, July 1 – September 30 Kancera AB (publ.), org.no. 556806-8851
2024-11-12
Kancera focuses on cardiovascular diseases
2024-11-01
Kancera appoints Robert Edfors as Chief Medical Officer

Events

No upcoming events are currently in the calendar

Presentations

https://www.redeye.se/videoiframe/1063175

Kancera’s presentation at the Redeye Technology & Life Science Day 2024